Development of Antibiotic Resistant Bacteria Technology by Molecular Detection Inc. (MDI),

July 12, 2011

"MDI's product the Detect-Ready MRSA Panel."

MDI's Detect-Ready MRSA Panel

According to a press release issued on July 12, 2011, Molecular Detection Inc. has “announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application titled ‘Methods, Compositions and Kits for Detection and Analysis of Antibiotic Resistant Bacteria.'”

The allowed claims will cover a key research component of MDI’s PCR-based technology platform.  According to the press release, that platform “accurately distinguishes between samples containing MRSA (methicillin resistant Staphylococcus aureus), MSSA (methicillin sensitive S. aureus) and mixed populations of bacteria by amplifying and evaluating multiple gene targets.”

“Allowance of these claims confirms that MDI’s approach is indeed state-of-the-art,” said Todd Wallach, CEO and chairman of MDI. “They add legal backing to a growing body of independent data confirming that our Detect-Ready panel is the most technically advanced MRSA screening test available today, and effectively raise the bar for other screening products. The allowance includes broad method and kit claims, and we expect that the issued patent will serve as a powerful resource in our drive to achieve leadership in the molecular detection of resistant pathogens, a large and growing healthcare problem worldwide.”

MDI’s first product, the Detect-Ready MRSA Panel, is a qualitative real-time PCR in vitro diagnostic test that is marketed in the European Union and Australia and is in late-stage development in the US. Its CE-mark label was recently expanded to include the detection of colonization with MSSA and other bacteria, in addition to MRSA. Detect-Ready is the only marketed PCR-based MRSA screening test with the proven ability to accurately discriminate between these pathogens, thereby minimizing the false positive results experienced with other MRSA screening tests and ensuring that clinicians and healthcare facilities have the timely and reliable information they need to assess and minimize patient risk.

Mr. Wallach added, “We are especially pleased with the allowed claims in view of the fact that the FDA has issued draft guidelines for MRSA screening tests that require the discrimination and accuracy enabled by our proprietary technology. Plans for our US validation trial are progressing well, with US launch targeted for 2012.”

Source:  Molecular Detection Inc. Receives Notice of Allowance for US Patent Application Broadly Covering Detection of Antibiotic-Resistant Bacteria.  PR Newswire, July 12, 2011.

Leave a Comment

Previous post:

Next post: